摘要
目的观察补肺通络丸联合甲氨蝶呤治疗早期类风湿关节炎肺间质病变(RA-ILD)的临床疗效及安全性。方法选择符合纳入标准的患者64例,随机分为治疗组和对照组各32例,治疗组在甲氨蝶呤基础上口服补肺通络丸,对照组继续单用甲氨蝶呤,治疗6个月后比较两组患者肺功能指标及高分辨率CT(HRCT)治疗前后的变化。结果治疗后治疗组的肺总量(TLC)、一氧化碳弥散量(DLCO)较治疗前明显改善(P<0.01),其HRCT评分较治疗前减小(P<0.05),两组治疗后的TLC、DLCO、HRCT结果比较差异有统计学意义(P<0.01或P<0.05)。结论补肺通络丸联合甲氨蝶呤治疗早期RA-ILD能明显改善肺功能,缩小肺间质病变面积,疗效确切,安全性好。
Objective To observe the effect and safety of Bufei Tongluo Wan （Bolus for tonifying the lung and removing obstruction of meridians） combined with methotrexate on rheumatoid arthritis associated interstitial lung disease （RA-ILD） in an early stage. Methods Sixty-four patients were randomized into two groups with 32 in each. The observation group was treated with Bufei Tongluo Wan and methotrexate for oral taking, while the control group treated with methotrexate only in continuation. After treatment for six months, the indices of lung function and changes in high resolution computer tomography （HRCT） of both groups were compared to observe the effect. Results After treatment, the total lung capacity （TLC） and diffusing capacity carbon monoxide （DLCO） of the observation group were significantly improved （P〈0.01） ; and its HRCT score was reduced （P〈0. 05）. The result of TLC, DLCO, and HRCT of the two groups in comparison after treatment showed statistical difference （P〈0.01 or P〈0.05）. Conclusion Bufei Tongluo Wan combined with methotrexate in the treatment of RA-ILD in an early stage is effective in improving the lung function and decreasing the area of interstitial lung lesions with a good safety.
出处
《中医杂志》
CSCD
北大核心
2011年第14期1213-1216,共4页
Journal of Traditional Chinese Medicine
关键词
类风湿关节炎
肺间质病变
补肺通络丸
甲氨蝶呤
肺功能
高分辨率CT
rheumatoid arthritis associated interstitial lung disease （RA-ILD）
Bufei Tongluo Wan （Bolus for tonifying the lung and removing obstruction of meridians）
methotrexate
lung function
high-resolution CT
